Incidence of relapse after allogeneic BMT.

(Top) Low-risk patients (n = 64) and (bottom) high-risk patients (n = 49) were divided into 3 groups according to the numbers of CD4^bright DCs they received in the bone marrow allograft (Figure 3). Relapse increased proportionally to the content of CD4^bright DCs in the graft. Log-rank statistic comparing the incidence of relapse between low-risk recipients of smaller (○)(group 1_(DC), n = 26) versus larger numbers of DC (▵)(group 3_(DC), n = 15) was 6.5 (P = .01). Log-rank statistic comparing the incidence of relapse between high-risk recipients of smaller versus intermediate numbers of DC (■)(group 1_(DC), n = 9 vs group 2_(DC), n = 25) was 2.5 (P = .1).